Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Women's Health and Genetics/Laboratory Corporation of America, |
RCV001806792 | SCV002051219 | likely pathogenic | Usher syndrome | 2021-12-17 | criteria provided, single submitter | clinical testing | Variant summary: CLRN1 c.190G>A (p.Gly64Arg) results in a non-conservative amino acid change in the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant was absent in 251472 control chromosomes (gnomAD). c.190G>A has been reported in the literature in a compound heterozygous individual and a homozygous individual affected with Usher Syndrome (Jiang_2015, Zhao_2015). These data indicate that the variant is likely to be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014. Based on the evidence outlined above, the variant was classified as likely pathogenic. |
Labcorp Genetics |
RCV002541387 | SCV003525465 | pathogenic | not provided | 2023-03-02 | criteria provided, single submitter | clinical testing | This sequence change replaces glycine, which is neutral and non-polar, with arginine, which is basic and polar, at codon 64 of the CLRN1 protein (p.Gly64Arg). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with Usher syndrome (PMID: 25472526, 26338283). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 1331448). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. For these reasons, this variant has been classified as Pathogenic. |
Baylor Genetics | RCV003470922 | SCV004214412 | likely pathogenic | Retinitis pigmentosa 61 | 2024-03-19 | criteria provided, single submitter | clinical testing |